Variables | Univariate analysis | |
---|---|---|
Responders (IgG > 15 AU/mL) | p (*) | |
Age | ||
< 72 years (n = 21) | 19 (90.5%) | 0.663 |
> 72 years (n = 21) | 17 (81%) | |
Gender | ||
M (n = 20) | 17 (85%) | 1 |
F (n = 22) | 19 (86.4%) | |
Body mass index (kg/sm2) | ||
< 25.5 (n = 20) | 19 (95%) | 0.187 |
> 25.5 (n = 22) | 17 (77.3%) | |
Lines of therapy | ||
1 (n = 31) | 26 (83.9%) | 1 |
> 1 (n = 11) | 10 (90.9%) | |
Lymphocyte count | ||
< 1600/µL (n = 21) | 16 (76.2%) | 0.184 |
> 1600/µL (n = 21) | 20 (95.2%) | |
Neutrophils count | ||
< 4980/µL (n = 21) | 20 (95.2%) | 0.184 |
> 4980/µL (n = 21) | 16 (76.2%) | |
Time from diagnosis to vaccination | ||
< 62 months (n = 21) | 16 (76.2%) | 0.184 |
62 months (n = 21) | 20 (95.2%) | |
Time from the start of ongoing therapy to vaccination | ||
< 37 months (n = 21) | 18 (85.7%) | 1 |
> 37 months (n = 21) | 18 (85.7%) | |
Diagnosis | ||
Myelofibrosis (n = 10) | 6 (60%) | 0.021 |
Polycythemia vera/essential thrombocythemia (n = 32) | 30 (93.8%) | |
Treatment | ||
Ruxolitinib (n = 8) | 5 (62.5%) | 0.072 |
Hydroxycarbamide/anagrelide/interferon alpha (n = 34) | 31 (91.2%) |